LEADER 00910nam0-22002771i-450- 001 990001717590403321 005 20160329104206.0 035 $a000171759 035 $aFED01000171759 035 $a(Aleph)000171759FED01 035 $a000171759 100 $a20030910d1964----km-y0itay50------ba 101 0 $aita 200 1 $aLavori della Società italiana di biogeografia$eX congresso nazionale, Sassari, 27-31 maggio 1964$fSocietà Italiana di Biogeografia 210 $aSassari$cIstituto di entomologia agraria dell'Università di Sassari$d1964 215 $a226 p.$d24 cm 610 0 $aBiogeografia 676 $a574.9 710 02$aSocietà italiana di biogeografia$064384 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990001717590403321 952 $a60 551 B 85$b40663$fFAGBC 959 $aFAGBC 996 $aLavori della Società italiana di biogeografia$9359167 997 $aUNINA LEADER 07362nam 22016215 450 001 9910459356203321 005 20210108052937.0 010 $a1-282-93564-X 010 $a9786612935640 010 $a1-4008-3045-1 024 7 $a10.1515/9781400830459 035 $a(CKB)2670000000060905 035 $a(EBL)617247 035 $a(OCoLC)697175317 035 $a(SSID)ssj0000467361 035 $a(PQKBManifestationID)11342604 035 $a(PQKBTitleCode)TC0000467361 035 $a(PQKBWorkID)10489794 035 $a(PQKB)10113106 035 $a(DE-B1597)446672 035 $a(OCoLC)979757915 035 $a(DE-B1597)9781400830459 035 $a(MiAaPQ)EBC617247 035 $a(EXLCZ)992670000000060905 100 $a20190708d2009 fg 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aBoundaries of Contagion $eHow Ethnic Politics Have Shaped Government Responses to AIDS /$fEvan Lieberman 205 $aCourse Book 210 1$aPrinceton, NJ : $cPrinceton University Press, $d[2009] 210 4$d©2009 215 $a1 online resource (368 p.) 300 $aDescription based upon print version of record. 311 $a0-691-14019-7 327 $t Frontmatter -- $tContents -- $tIllustrations -- $tAbbreviations -- $tPreface -- $t1. Introduction -- $t2. A Theory Of Boundary Politics And Alternative Explanations -- $t3. Globalization And Global Governance Of Aids: The Geneva Consensus -- $t4. Race Boundaries And Aids Policy In Brazil And South Africa -- $t5. A Model-Testing Case Study Of Strong Ethnic Boundaries And Aids Policy In India -- $t6. Ethnic Boundaries And Aids Policies Around The World -- $t7. Conclusion: Ethnic Boundaries Or Cosmopolitanism? -- $tReferences -- $tIndex 330 $aWhy have governments responded to the HIV/AIDS pandemic in such different ways? During the past quarter century, international agencies and donors have disseminated vast resources and a set of best practice recommendations to policymakers around the globe. Yet the governments of developing countries in sub-Saharan Africa, Asia, Latin America, and the Caribbean continue to implement widely varying policies. Boundaries of Contagion is the first systematic, comparative analysis of the politics of HIV/AIDS. The book explores the political challenges of responding to a stigmatized condition, and identifies ethnic boundaries--the formal and informal institutions that divide societies--as a central influence on politics and policymaking. Evan Lieberman examines the ways in which risk and social competition get mapped onto well-institutionalized patterns of ethnic politics. Where strong ethnic boundaries fragment societies into groups, the politics of AIDS are more likely to involve blame and shame-avoidance tactics against segments of the population. In turn, government leaders of such countries respond far less aggressively to the epidemic. Lieberman's case studies of Brazil, South Africa, and India--three developing countries that face significant AIDS epidemics--are complemented by statistical analyses of the policy responses of Indian states and over seventy developing countries. The studies conclude that varied patterns of ethnic competition shape how governments respond to this devastating problem. The author considers the implications for governments and donors, and the increasing tendency to identify social problems in ethnic terms. 606 $aAIDS (Disease) -- Government policy -- Comparative studies 606 $aAIDS (Disease) -- Political aspects -- Comparative studies 606 $aEthnic relations -- Political aspects 606 $aAIDS (Disease)$xGovernment policy$vComparative studies 606 $aAIDS (Disease)$xPolitical aspects$vComparative studies 606 $aEthnic relations$xPolitical aspects 606 $aImmunologic Deficiency Syndromes 606 $aCulture 606 $aPublic Policy 606 $aSexually Transmitted Diseases, Viral 606 $aSlow Virus Diseases 606 $aInternational Cooperation 606 $aPopulation Groups 606 $aLentivirus Infections 606 $aDemography 606 $aVirus Diseases 606 $aInternationality 606 $aSocial Control Policies 606 $aImmune System Diseases 606 $aAnthropology, Cultural 606 $aPersons 606 $aSexually Transmitted Diseases 606 $aRetroviridae Infections 606 $aPopulation Characteristics 606 $aSociology 606 $aDiseases 606 $aPolicy 606 $aRNA Virus Infections 606 $aNamed Groups 606 $aSocial Sciences 606 $aAnthropology 606 $aHealth Care 606 $aSocial Control, Formal 606 $aHealth Care Economics and Organizations 606 $aAnthropology, Education, Sociology and Social Phenomena 606 $aEthnic Groups 606 $aHIV Infections 606 $aAcquired Immunodeficiency Syndrome 606 $aDeveloping Countries 606 $aEthnology 606 $aHealth Policy 606 $aCross-Cultural Comparison 606 $aPublic Health$2HILCC 606 $aHealth & Biological Sciences$2HILCC 606 $aCommunicable Diseases$2HILCC 608 $aElectronic books. 615 4$aAIDS (Disease) -- Government policy -- Comparative studies. 615 4$aAIDS (Disease) -- Political aspects -- Comparative studies. 615 4$aEthnic relations -- Political aspects. 615 0$aAIDS (Disease)$xGovernment policy 615 0$aAIDS (Disease)$xPolitical aspects 615 0$aEthnic relations$xPolitical aspects 615 2$aImmunologic Deficiency Syndromes 615 2$aCulture 615 2$aPublic Policy 615 2$aSexually Transmitted Diseases, Viral 615 2$aSlow Virus Diseases 615 2$aInternational Cooperation 615 2$aPopulation Groups 615 2$aLentivirus Infections 615 2$aDemography 615 2$aVirus Diseases 615 2$aInternationality 615 2$aSocial Control Policies 615 2$aImmune System Diseases 615 2$aAnthropology, Cultural 615 2$aPersons 615 2$aSexually Transmitted Diseases 615 2$aRetroviridae Infections 615 2$aPopulation Characteristics 615 2$aSociology 615 2$aDiseases 615 2$aPolicy 615 2$aRNA Virus Infections 615 2$aNamed Groups 615 2$aSocial Sciences 615 2$aAnthropology 615 2$aHealth Care 615 2$aSocial Control, Formal 615 2$aHealth Care Economics and Organizations 615 2$aAnthropology, Education, Sociology and Social Phenomena 615 2$aEthnic Groups 615 2$aHIV Infections 615 2$aAcquired Immunodeficiency Syndrome 615 2$aDeveloping Countries 615 2$aEthnology 615 2$aHealth Policy 615 2$aCross-Cultural Comparison 615 7$aPublic Health 615 7$aHealth & Biological Sciences 615 7$aCommunicable Diseases 676 $a614.4 700 $aLieberman$b Evan, $0499844 801 0$bDE-B1597 801 1$bDE-B1597 906 $aBOOK 912 $a9910459356203321 996 $aBoundaries of Contagion$92471169 997 $aUNINA LEADER 01178nam a2200265 i 4500 001 991002211129707536 005 20020507161350.0 008 000719s1995 it ||| | ita 020 $a8813195567 035 $ab11624656-39ule_inst 035 $aLE02732337$9ExL 040 $aDip.to Studi Giuridici$bita 082 $a345.4505 100 1 $aConso, Giovanni$0149594 245 10$aProfili del nuovo codice di procedura penale :$bAppendice di aggiornamento con la legge 8 agosto 1995, n. 332 :$bModifiche al codice di procedura penale in tema di semplificazione dei procedimenti, di misure cautelari e di diritto di difesa /$cGiovanni Conso, Vittorio Grevi 250 $a3. ed. 260 $aPadova :$bCEDAM,$c1995 300 $a77 p. ;$c24 cm. 700 1 $aGrevi, Vittorio$eauthor$4http://id.loc.gov/vocabulary/relators/aut$0222797 907 $a.b11624656$b10-03-11$c02-07-02 912 $a991002211129707536 945 $aLE027 345.45 CON01.04$g1$i2027000164349$lle027$o-$pE0.00$q-$rl$s- $t0$u3$v0$w3$x0$y.i11842519$z02-07-02 996 $aProfili del nuovo codice di procedura penale$9577078 997 $aUNISALENTO 998 $ale027$b01-01-00$cm$da $e-$fita$git $h0$i1 LEADER 10877nam 2200505 450 001 9910503001003321 005 20230920103049.0 010 $a3-030-78315-4 035 $a(CKB)4100000012037515 035 $a(MiAaPQ)EBC6736351 035 $a(Au-PeEL)EBL6736351 035 $a(OCoLC)1272855295 035 $a(PPN)258057300 035 $a(EXLCZ)994100000012037515 100 $a20220625d2021 uy 0 101 0 $aeng 135 $aurcnu|||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aNuclear receptors $ethe art and science of modulator design and discovery /$fMostafa Z. Badr, editor 210 1$aCham, Switzerland :$cSpringer,$d[2021] 210 4$d©2021 215 $a1 online resource (676 pages) 311 $a3-030-78314-6 327 $aIntro -- Preface -- Contents -- About the Editor -- Chapter 1: Molecular Pharmacology of the Youngest Member of the Nuclear Receptor Family: The Mineralocorticoid Receptor -- 1.1 An Overview of the MR Physiology -- 1.2 Evolutionary Profile of the MR -- 1.3 The Hsp90-Based Heterocomplex -- 1.4 MR Trafficking -- 1.5 Agonist Structure-Activity Relationship -- 1.6 MR Antagonism -- 1.7 MR Regulation by Phosphorylation and Redox Potential -- 1.8 Conclusions -- References -- Chapter 2: A Simple Method for Visual Assessment and Quantification of Altered Subcellular Localization of Nuclear Receptors -- 2.1 Introduction -- 2.2 Materials and Methods -- 2.3 Notes -- References -- Chapter 3: Multifaceted Effects of Ligand on Nuclear Receptor Mobility -- 3.1 Introduction -- 3.2 Nucleocytoplasmic Shuttling of the Nuclear Receptors -- 3.2.1 Nuclear Pore Complexes: Gatekeepers of the Nucleus -- 3.2.2 Nuclear Import Pathways -- 3.2.3 Nuclear Export Pathways -- 3.2.4 Dynamics of Movement Within the Nucleus -- 3.3 Ligand-Dependent Nuclear Accumulation of Nuclear Receptors -- 3.3.1 Glucocorticoid Receptor Nuclear Accumulation and Intranuclear Dynamics -- 3.3.1.1 GR Nuclear Accumulation -- 3.3.1.2 GR Intranuclear Dynamics -- 3.3.2 Mineralocorticoid Receptor Nuclear Accumulation and Intranuclear Dynamics -- 3.3.2.1 MR Nuclear Accumulation -- 3.3.2.2 MR Intranuclear Dynamics -- 3.3.3 Androgen Receptor Nuclear Accumulation and Intranuclear Dynamics -- 3.3.3.1 Androgen Receptor Nuclear Accumulation -- 3.3.3.2 Androgen Receptor Intranuclear Dynamics -- 3.4 Ligand-Dependent Intranuclear Localization -- 3.5 Ligand-Independent Trafficking -- 3.5.1 Thyroid Hormone Receptor Intracellular Trafficking -- 3.5.2 Retinoic Acid Receptor Intracellular Trafficking -- 3.6 Retinoid X Receptor and Vitamin D Receptor Intracellular Trafficking: A Bin of Their Own? -- 3.7 Conclusions. 327 $aReferences -- Chapter 4: Chemical Considerations in Discovery of Receptor Modulators -- 4.1 Introduction -- 4.2 Intermolecular Binding Forces Drive Ligand Action -- 4.3 Sterics and Hydrophobicity in Ligand Binding -- 4.4 Stereochemical Considerations -- 4.5 Molecular Dynamics as a Tool for Modulator Design -- 4.6 Case Study: A Holistic Approach to Liver X Receptor Modulator Design -- 4.7 Conclusions -- References -- Chapter 5: Structure-Based Design of Estrogen-Related Receptors Modulators -- 5.1 Introduction -- 5.2 Structure and Function -- 5.3 Medicinal Chemistry of ERR Modulators -- 5.3.1 ERR Inverse Agonists -- 5.3.2 ERRs Agonists -- References -- Chapter 6: PPAR? and ? Ligand Design: Honing the Traditional Empirical Method with a More Holistic Overview -- 6.1 Introduction to the PPAR Protein -- 6.1.1 Overall PPAR LBD Protein Structure -- 6.1.2 Mechanism of PPAR Gene Transcription -- 6.1.3 Differences in LBD Between PPAR Subtypes -- 6.2 Catalogue of Known Ligands -- 6.2.1 PPAR? Ligands -- 6.2.1.1 PPAR? Full Agonists -- WY14643 or Pirinixic Acid -- GW590735/Compound 25a -- Pemafibrate -- 6.2.1.2 PPAR? Antagonist -- GW6471 -- 6.2.2 PPAR? Ligands -- 6.2.2.1 PPAR? Full Agonists -- GW2433 -- GW2331 -- LC1765 -- Compound 48 -- Isoquinoline Compound 5 -- TIPP-204 -- GW0742 -- GW501516, Compounds 1-16 -- Compound 18 and Compound 13 -- 6.2.2.2 PPAR? Partial Agonists -- Compound 2 -- GW9371 -- 6.2.3 Dual or Pan Agonist Ligands -- 6.2.3.1 PPAR?/? Dual Agonists -- GW409544 -- Azetidinone Compounds 17 and 35 -- GL479 -- 6.2.3.2 PPAR?/? Dual Agonists -- TIPP-401 -- 6.2.3.3 PPAR?/? Dual Agonists -- Phenoxyacetic Acid Compounds 10 and 21 -- Sulfonylthiadiazole Compounds 6, 11t and 20a -- 6.2.3.4 Pan Agonists -- Indeglitazar -- TIPP-703 -- AL29-26 -- 6.2.3.5 Endogenous Agonists -- Eicosapentaenoic Acid (20:5 EPA) -- Vaccenic Acid (18:1) -- Iloprost. 327 $a17(S)-oxoDHA (22:6) -- 6.3 Ligand Design Factors -- 6.4 Tools and New Information -- 6.4.1 Examples of Computer-Aided Drug Design -- 6.4.2 Pharmacokinetics and Pharmacodynamics -- 6.4.3 Wider Considerations for PPAR -- 6.4.3.1 LBD Mutations -- 6.4.3.2 PPAR Intact Structure and Implications -- 6.4.3.3 Coregulators and FABPs -- 6.5 Conclusion -- References -- Chapter 7: Pregnane X Receptor: Understanding Its Function and Activity at the Molecular Level -- 7.1 Introduction -- 7.2 The Chemical Landscape of PXR Ligands -- 7.3 The Structural Architecture of PXR -- 7.4 Dimerization of PXR -- 7.5 Coregulatory Recruitment to PXR -- 7.6 AF-2 Helix Orientation Dictates PXR's Activation -- 7.7 Ligand Binding Stabilizes the Structure of PXR -- 7.8 Ligand-Binding Site of PXR and Ligand Promiscuity -- 7.9 Species Selectivity in PXR Activation -- 7.10 PXR Inhibitors -- 7.11 PXR Agonists as Therapeutics -- 7.12 Conclusion -- References -- Chapter 8: Strategies for the Design of Vitamin D Receptor Ligands -- 8.1 Introduction -- 8.2 Secosteroid VDR Ligands -- 8.3 Non-secosteroid VDR Ligands -- 8.4 VDR Antagonists -- 8.5 Concluding Remarks and Future Directions -- References -- Chapter 9: What Makes a Good Antagonist: Lessons Learned from the Estrogen and Aryl Hydrocarbon Receptors -- 9.1 Introduction: What Is an Antagonist? -- 9.2 Identification and Development of ER Antagonists -- 9.2.1 A Brief History of the Development of ER Antagonists -- 9.2.2 Molecular Characterization of ERs -- 9.2.3 The Antagonistic Activity of SERMs Involves Repositioning of Helix 12 -- 9.2.4 Additional Classes of ER? Antagonists -- 9.3 Development of AHR Antagonists -- 9.3.1 Early Days of AHR Discovery -- 9.3.2 Molecular Structure of the AHR -- 9.3.3 Agonist-Induced Activation of the AHR -- 9.3.4 The AHR Is Activated by a Diverse Cadre of Ligands. 327 $a9.3.5 Development of Selective AHR Modulators (SAHRMs) -- 9.3.6 Toward the Development of "Pure" AHR Antagonists -- 9.3.7 Development of Flavone-Based AHR Antagonists -- 9.3.8 Development of Indole-Based AHR Antagonists -- 9.3.9 Development of Stilbene-Based AHR Antagonists -- 9.3.10 Development of AHR-PROTACs (SAHRDs) -- 9.3.11 Elucidating the Rules That Govern Agonist Versus Antagonist-Induced AHR Activity -- 9.4 Conclusions and Future Directions -- References -- Chapter 10: Design of Novel PPAR Agonist for Neurodegenerative Disease -- 10.1 Introduction -- 10.2 Overview of PPARs and Their Structures -- 10.3 PPAR-Gamma Activation Site -- 10.4 Structure of the Ligand-Binding Domain -- 10.5 Structural Dynamics of PPAR Gamma -- 10.6 Selective PPAR Modulators (SPPARMs) -- 10.7 PPAR Delta Active Site Description -- 10.8 PPAR Alpha Active Site Description -- 10.9 PPARS and Neurodegenerative Diseases -- 10.10 PPARS for Alzheimer's Disease: Overview of AD -- 10.11 PPARs and Neuroinflammation -- 10.12 PPARs and Microglia and Neurotrophins -- 10.13 PPARS, TREM2, and Amyloid Beta -- 10.14 Conclusion -- References -- Chapter 11: Functional Bioassays Lithograph Ligand Reflections in the PPAR? Sphere -- 11.1 PPARs Are Nuclear Hormone Receptors -- 11.2 The RXR Obligation -- 11.3 Screening for PPAR Activators -- 11.4 Reporter Plasmids of PPAR-RXR Heterodimer Activity -- 11.5 Power of the Imperfect -- 11.6 Is It a Ligand? -- 11.7 Saturation and Competition-Binding Analyses -- 11.8 Ligand-Dependent Conformational Change -- 11.9 Altered DNA-Binding Affinity -- 11.10 Crystal Structure -- 11.11 Summary -- References -- Chapter 12: Computational Applications on Food Contact Chemicals as Nuclear Receptor Binders -- 12.1 Introduction -- 12.2 Methods to Evaluate Food Contaminants as Nuclear Receptor Modulators. 327 $a12.3 In Vitro Bioassays to Study the Mechanism of Action (MoA) of Endocrine Disruptor Compounds -- 12.3.1 Ligand-Binding Assays -- 12.3.2 Gene Reporter Assays -- 12.3.3 Steroidogenesis Assay -- 12.4 In Silico Methods for Screening Endocrine Disruptor Compounds -- 12.4.1 3D Protein Structure: The Starting Point of Computational Methods -- 12.4.2 Ligand-Based Virtual Screening -- 12.4.3 Molecular Docking -- 12.4.4 Consensus Scoring -- 12.4.5 Molecular Dynamic Simulations -- 12.5 Case Studies -- References -- Chapter 13: Nuclear Hormone Receptors and Host-Virus Interactions -- 13.1 Introduction -- 13.2 Nuclear Receptor Structure and Function -- 13.3 PPAR Signaling and Host-Virus Interactions -- 13.3.1 PPARs and Hepatitis C Virus (HCV) -- 13.3.2 PPARs and Flaviviruses -- 13.3.3 PPARs and Human Immunodeficiency Virus (HIV) -- 13.3.4 PPARs and Other Examples of Viruses -- 13.3.4.1 Hepatitis B Virus -- 13.3.4.2 Influenza A Viruses (IAVs) -- 13.3.4.3 Herpesviruses -- 13.4 Liver X Receptors (LXRs) and Host-Virus Interactions -- 13.4.1 LXR and HCV -- 13.4.2 HIV-1 and LXR -- 13.4.3 LXR and Other Examples of Viruses -- 13.4.3.1 Influenza A Viruses -- 13.4.3.2 Herpesviruses and LXR -- 13.4.3.3 HBV -- 13.5 FXR and Host-Virus Interactions -- 13.5.1 FXR Signaling -- 13.5.2 FXR Signaling During HCV Infection -- 13.5.3 FXR Signaling During HBV Infection -- 13.6 Conclusions -- References -- Chapter 14: Retinoic Acid-Related Orphan Receptor (ROR) Inverse Agonists: Potential Therapeutic Strategies for Multiple Inflammatory Diseases? -- 14.1 Introduction -- 14.2 Functions of RORs in Immune Cells -- 14.3 RORs and Autoimmune Disease -- 14.4 Vitamin D3, VDR, and RORs -- 14.5 Multiple Sclerosis (MS) -- 14.6 Psoriasis -- 14.7 Role of ROR? in Cardiac Injury and Heart Failure -- 14.8 RORs in Asthma and Acute Respiratory Distress Syndrome (ARDS) -- 14.9 Rheumatoid Arthritis. 327 $a14.10 Sjögren's Syndrome (SS). 606 $aNuclear receptors (Biochemistry) 606 $aReceptors nuclears (Bioquímica)$2thub 608 $aLlibres electrònics$2thub 615 0$aNuclear receptors (Biochemistry) 615 7$aReceptors nuclears (Bioquímica) 676 $a572.8845 702 $aBadr$b Mostafa Z.$f1950- 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910503001003321 996 $aNuclear receptors$983646 997 $aUNINA LEADER 01355nam0 22003131i 450 001 UON00455395 005 20231205105101.384 100 $a20150605f1964 |0itac50 ba 101 $afre 102 $aFR 105 $a|||| 1|||| 200 1 $a19. [dix-neuvième] siècle$eles grands auteurs français du programme$fAndré Lagarde, Laurent Michard 210 $aParis$cBordas$dc1964 215 $a576 p., [32] c. di tav.$cill.$d22 cm. 316 $aValore stimato$5IT-UONSI FranceseVII/423 410 1$1001UON00247730$12001 $aCollection littéraire Lagarde et Michard$1210 $aParis$cBordas$v5 606 $aLetteratura francese$xSec. 19.$xAntologie$3UONC064188$2FI 606 $aLetteratura francese$xStoria$xSec. 19.$3UONC064116$2FI 620 $aFR$dParis$3UONL002984 676 $a840.7$cLetteratura francese. Monarchia costituzionale, 1815-1848$v21 700 1$aLAGARDE$bAndré$3UONV123556$0388693 701 1$aMICHARD$bLaurent$3UONV123557$0174779 712 $aBordas$3UONV247138$4650 801 $aIT$bSOL$c20251017$gRICA 899 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$2UONSI 912 $aUON00455395 950 $aSIBA - SISTEMA BIBLIOTECARIO DI ATENEO$dSI VII 423 $eSI SFR2157/1 7 423 Valore stimato 996 $a19. siècle$91250370 997 $aUNIOR